{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-015683","form_type":"8-K/A","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.803431+00:00","generated_at":"2026-05-26T08:36:31.444583+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"NeuroOne stockholders approve 2025 Equity Incentive Plan and reverse stock split","bullets":["Approved 2025 Equity Incentive Plan authorizing up to 3M new shares plus returning shares from prior plan.","Approved reverse stock split at ratio of 1:2 to 1:15, with exact ratio to be set by the Board.","David Rosa re-elected as Class II director with 11.7M votes for, 381.7K withheld, 6.0M broker non-votes.","Ratified Baker Tilly U.S., LLP as independent auditor for FY2025 with 18.1M votes for, 7.4K against.","Adjournment proposal also approved, with 16.8M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-015683","json":"https://secwatch.observer/filing/0001213900-25-015683.json","markdown":"https://secwatch.observer/filing/0001213900-25-015683.md","text":"https://secwatch.observer/filing/0001213900-25-015683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/0001213900-25-015683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/ea0231612-8ka1_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T08:36:31.444583+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}